BSD Medical is Now Pyrexar Medical

The complete line of BSD Hyperthermia products are availble thru Pyrexar Medical

Great opportunity to view the International Journal of Hyperthermia for free. Volume 34, Issue 2 has been set to "free access" until May 30th, 2018.

Issue highlights editorials and reviews on the role of thermal therapy with infectious diseases.  If you want access to all of the issues of the IJH, the most cost efficient way to become an STM or ESHO member.  Membership provides additional cost benefits to the corresponding conferences, but it also helps build and promote hyperthermia research and treatment expansion throught the world.


The Journal of the American Medical Association (JAMA) just published a 10 year patient follow-up to a phase III clinical study on a Soft Tissue Sarcoma Study.

STS Infographic thumb

With Invited Commentary - Technological Advances, Biologic Rationales, and the Associated Success of Chemotherapy With Hyperthermia in Improved Outcomes in Patients With Sarcoma by Mark W. Dewhirst, DVM, PhD; David Kirsch, MD, PhD

Under the organization of the European Society of Hyperthermic Oncology the study was conducted in 9 centers located in Germany, Norway, Austria and the United States using the BSD-2000 Deep Regional Hyperthermia System. This study enrolled 365 soft tissue sarcoma patients (18-70 years old) that were matched and entered into a double blind study. One group received neoadjuvant chemotherapy consisting of doxorubicin, ifosfamide, and etoposide [CT] treatment and the other group received the same chemotherapy along with a course of hyperthermia [HT].

For non-clinicians, we have done our best to provide the salient points in the above info-graphic. The full article can be found on the JAMA website here.

We feel that the results are astonishing. The HEADLINE: chemotherapy plus hyperthermia equals better results and extended life. #heatmatters

13 new countries 2In our efforts to bring hyperthermia cancer treatment to the world, we are welcoming three new distribution, sales and service companies covering 13 countries.

medvision 250px

MedVision, a division of SADITA Holdings Group, is well known in the areas of cardiology, cardiac surgery and peripheral intervention products. The company will be representing Pyrexar Medical in their home country of Kuwait, as well as, Qatar, Bahrain, Saudi Arabia, Lebanon, Jordan, Egypt, UAE, Oman, Iraq & Iran. This represents a major expansion in the Middle East for Pyrexar and we are looking forward to growing with them.

TemaSinergie 250px

Tema Sinergie is based in Faenza, Italy in the coastal province of Ravenna. The company's motto is "high tech, high care" and they have certainly been living up to that vision.  Tema specializes in nuclear medicine, radiotherapy, uro-oncology, barrier solution technology and medical physics. The group has been serving the country's need for medical products for over 30 years. Hyperthermia is an excellent extension of their product line and we are excited to have them on our team.

meyra turkey logo

Meyra Medicine and Health Products, will be bringing Pyrexar Medical's hyperthermia product line to Turkey. Meyra, which translates to "shining star" is headquartered outside the coastal city of Izmir in the town of Kemalpasa, Turkey. In addition to sales and service support of hyperthermia, the company is also involved in ultrasound imaging products and proton therapy systems. Turkey is an emerging market economy with a healthy medical technology sector.

Please join us in welcoming our new members to the Pyrexar team.

A friendly reminder that the main Hyperthermia conference events in the US and Europe, STM and ESHO, are right around the corner. These conferences are a gathering of the best in hyperthermia research and an excellent resource for those interested in the field of thermal oncology.

The 35th Annual Meeting of the Society for Thermal Medicine and the 32nd Annual Meeting of the European Society for Hyperthermic Oncology will provide an arena for presentations of latest data, concepts, and breakthroughs in our ever-expanding understanding of thermal medicine in the context of engineering, physics, materials science, and biology.

Keynote and Plenary speakers will highlight the extensive connections between physics, information science, biology, imaging, and the thermal state.

stm esho 2018

Who Should Attend?

  • Researchers in the field of thermal oncology
  • Clinicians, new to the field, who would like to talk with experts
  • Clinicians who want to expand their thermal oncology program
  • Medical Students that want to understand how hyperthermia may impact the future of medicine.
  • Pyrexar Distributors who want to expand their working knowledge of hyperthermia
  • Potential purchasers of hyperthermia equipment

Here are some dates to help you plan

Conference Dates: May 7-10 May 16-19
Location: Tuscon, Arizona Berlin, Germany
Venue: Westin La Paloma Resort Langenbeck-Virsho Hause
Abstract Deadline:  Feb 28th March 16th
Submit Abstract:
Early Bird Registration Deadline: Mar 16th Feb 28th
Conference Pass: $650 - $1300 € 350 - €500
Hotel: $109 €149 - €218
Show Website:

Hope to see you there!